Withdrawal: Makena
Apr. 2023Pharmacy Updates
On March 7, 2023, Covis Pharma announced that it is withdrawing Makena (hydroxyprogesterone caproate injection; also referred to as 17-OHPC) from the market. This drug is used to reduce the risk of preterm birth in women who are pregnant with one baby and have a history of spontaneous preterm birth. Read more about the Makena withdrawal.
Recent Announcements
Virtual Institute: Bridging the Gap: Foundations of Integrated Care CME Courses Available
Bridging the Gap: Foundations of Integrated Healthcare is a free educational series designed to support behavioral health and physical health providers in integrating physical health and wellness strategies into their practices and programs to support recovery of individuals living with serious mental illnesses. The series emphasizes tools, education, and resources that empower healthcare providers and individuals to become informed and effective managers of their health and health care.Jun. 2026Education/Webinars
Important information regarding Medicare GLP-1 Bridge through CMS
The Centers for Medicare & Medicaid Services (CMS) is expanding access to certain GLP-1 medications through the Medicare GLP-1 Bridge short-term demonstration starting July 1, 2026.Jun. 2026Important Notices
CME/CEU Webinar: Bright Beginnings: The Role of Medical and Dental Providers in Early Oral Health
Please join us for a live, CME-accredited and CEU-accredited webinar on Monday, Aug. 24 from noon to 1 p.m., that will educate providers on the importance of early childhood oral health.Jun. 2026Education/Webinars